BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 18947077)

  • 1. New prostate cancer drugs hold promise.
    Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897
    [No Abstract]   [Full Text] [Related]  

  • 2. New prostate cancer drug: Prostate cancer's day in the sun.
    Attard G; Reid AH; Dearnaley D; De Bono JS
    BMJ; 2008 Aug; 337():a1249. PubMed ID: 18694888
    [No Abstract]   [Full Text] [Related]  

  • 3. Abiraterone acetate.
    Logothetis CJ; Efstathiou E; Manuguid F; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Aug; 10(8):573-4. PubMed ID: 21804589
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA approves prostate cancer treatment that inhibits testosterone synthesis.
    Thompson CA
    Am J Health Syst Pharm; 2011 Jun; 68(11):960. PubMed ID: 21593221
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate cancer hope.
    Wallis L
    Nurs Stand; 2008 Oct 8-14; 23(5):21. PubMed ID: 18947077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
    Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
    [No Abstract]   [Full Text] [Related]  

  • 7. [Promising on advanced cancer, several new drugs coming].
    Widmark A; Karlsson CT
    Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
    Attard G; Belldegrun AS; de Bono JS
    BJU Int; 2005 Dec; 96(9):1241-6. PubMed ID: 16287438
    [No Abstract]   [Full Text] [Related]  

  • 9. [Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
    Takeda M; Hosaka M
    Nihon Rinsho; 2000 Jul; 58 Suppl():312-6. PubMed ID: 11022738
    [No Abstract]   [Full Text] [Related]  

  • 10. A new era for castrate resistant prostate cancer: a treatment review and update.
    Fong MK; Hare R; Jarkowski A
    J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
    Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
    Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.